Cortendo
Biotech · Acquired
Osilodrostat, a cortisol synthesis inhibitor molecule for treating Cushing's syndrome
cortendo.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3103 | TRIANGLE THERAPEUTICS INC. | — | — |
| 3104 | Thimble Therapeutics Inc | — | — |
| 3105 | EPIVAX, INC. | — | — |
| 3106 | Cortendo | — | — |
| 3107 | MICROPURE GENOMICS INC | — | — |
| 3108 | ERNEST PHARMACEUTICALS LLC | — | — |
| 3109 | MECHASIM INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.